Eton Pharmaceutcials, Inc. Common Stock (ETON) Stock Price

ETONStock

$59.78+245.95%52W

Market Cap$1.71B

P/E—

PEG Ratio—

Div yield—

Beta0.89

ETON Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)215.09%

Price vs S&P 500 (4W)30.89%

VGM Score62.49

P/CF (Annual)106.27x

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)10.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)55.53%

Cash Flow / Share (Quarterly)$0.02

Price vs S&P 500 (YTD)240.70%

Gross Margin (TTM)54.77%

Net Profit Margin (TTM)-1.70%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.68M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)357.25%

EPS (Annual)$-0.17

ROI (Annual)-8.11%

Gross Margin (Annual)53.46%

Net Profit Margin (5Y Avg)-13.99%

Cash / Share (Quarterly)$0.72

Revenue Growth QoQ (YoY)40.41%

ROA (Last FY)-4.99%

Revenue Growth TTM (YoY)79.89%

EBITD / Share (TTM)$0.22

ROE (5Y Avg)-23.87%

Operating Margin (TTM)2.35%

Cash Flow / Share (Annual)$0.38

P/B Ratio36.53x

P/B Ratio (Quarterly)22.00x

Net Income / Employee (Annual)$-104,600

EV / Revenue (TTM)12.99x

Net Interest Coverage (TTM)-0.23x

ROA (TTM)-1.49%

EV / EBITDA (TTM)182.12x

EPS Incl Extra (Annual)$-0.17

Current Ratio (Annual)1.57x

Quick Ratio (Quarterly)0.75x

3-Month Avg Trading Volume0.50M

52-Week Price Return245.95%

EV / Free Cash Flow (Annual)110.83x

Revenue / Employee (TTM)$1,975,800

Tangible BV / Share (Quarterly)$0.39

P/S Ratio (Annual)13.99x

Asset Turnover (Annual)0.87x

52-Week High$66.37

Operating Margin (5Y Avg)-11.57%

EPS Excl Extra (Annual)$-0.17

CapEx CAGR (5Y)46.12%

Tangible BV CAGR (5Y)-7.25%

26-Week Price Return227.02%

Quick Ratio (Annual)0.98x

13-Week Price Return87.63%

Total Debt / Equity (Annual)1.17x

Current Ratio (Quarterly)1.21x

Enterprise Value$1.13B

Revenue / Share Growth (5Y)335.35%

Asset Turnover (TTM)0.88x

Book Value / Share Growth (5Y)8.46%

Revenue / Employee (Annual)$1,817,000

Inventory Turnover (Annual)2.43x

Pretax Margin (Annual)-5.70%

Cash / Share (Annual)$0.96

3-Month Return Std Dev102.20%

Gross Margin (5Y Avg)66.90%

Net Income / Employee (TTM)$-33,500

EBITDA Interim CAGR (5Y)-8.48%

ROE (Last FY)-17.59%

Net Interest Coverage (Annual)0.58x

EPS Basic Excl Extra (Annual)$-0.17

P/FCF (TTM)51.33x

Receivables Turnover (TTM)5.83x

EV / Free Cash Flow (TTM)2620.69x

Total Debt / Equity (Quarterly)1.00x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)9.34x

ROI (TTM)-2.61%

P/S Ratio (TTM)12.87x

Pretax Margin (5Y Avg)-13.81%

Revenue / Share (Annual)$2.97

Tangible BV / Share (Annual)$0.42

Forward P/E35.33x

Price vs S&P 500 (52W)227.39%

Year-to-Date Return253.52%

5-Day Price Return-7.22%

EPS Normalized (Annual)$-0.17

ROA (5Y Avg)-11.23%

Net Profit Margin (Annual)-5.75%

Month-to-Date Return28.78%

Cash Flow / Share (TTM)$0.12

EBITD / Share (Annual)$0.12

Operating Margin (Annual)-1.06%

LT Debt / Equity (Annual)0.83x

P/CF (TTM)70.61x

ROI (5Y Avg)-14.79%

LT Debt / Equity (Quarterly)0.62x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)15.31x

P/B Ratio (Annual)17.34x

Inventory Turnover (TTM)2.80x

Pretax Margin (TTM)-1.71%

Book Value / Share (Annual)$0.97

Price vs S&P 500 (13W)85.68%

Beta0.89x

P/FCF (Annual)109.75x

Revenue / Share (TTM)$2.76

ROE (TTM)-5.68%

52-Week Low$14.27

vGradeF

gGradeA

mGradeA

vgmGradeB

ETON Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	$0.19	$0.43	+126.32%(+$0.24)
Q1 2026	May 14, 2026	$0.14	$0.14	+0.00%(+$0.00)
Q4 2025	Mar 19, 2026	$0.20	$0.19	-5.00%(-$0.01)
Q3 2025	Nov 6, 2025	$0.16	$0.04	-75.00%(-$0.12)
Q2 2025	Aug 7, 2025	$0.02	$0.03	+28.59%(+$0.01)

ETON Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

4.10

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ETONEton Pharmaceutcials, Inc. Common Stock	F	A	A	$59.78
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Eton Pharmaceutcials, Inc. Common Stock

Eton Pharmaceuticals is a specialty pharmaceutical company focused on rare diseases with significant unmet patient needs. The company markets four FDA-approved products addressing adrenocortical insufficiency, hyperammonemia, homocystinuria, and hereditary tyrosinemia type 1. Eton is advancing three late-stage product candidates, including an innovative hydrocortisone autoinjector, to expand its rare disease portfolio.

ETON Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.37

Revenue estimate$41.98M

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ETON Insider Transactions

SellAug 24, 2026
KREMPA DAVID
Officer
Shares: 25,000Value: $1.63M
SellAug 20, 2026
BRYNJELSEN SEAN E
Chief Executive Officer
Shares: 100,000Value: $6.09M
SellJul 14, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 28,315Value: $1.06M
SellJul 7, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 126,685Value: $4.77M
SellJun 17, 2026
ADAMS JENNIFER MCKIE
Director
Shares: 50,000Value: $1.62M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$14.27

High$66.37